The authors identified the molecular mechanism of Sonic hedgehog (Shh)-mediated mutation-independent Imatinib resistance that is most relevant for treating chronic myeloid leukemia-variants and non-compliant patients.
[Cell Death & Disease]
6445212
{6445212:G58D8JUM}
apa
50
1
160033
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-ef325263049d30880f802fe5c7ccc20c%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22G58D8JUM%22%2C%22library%22%3A%7B%22id%22%3A6445212%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Anusha%20et%20al.%22%2C%22parsedDate%22%3A%222021-03-11%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EAnusha%2C%20Dalal%2C%20H.%2C%20Subramanian%2C%20S.%2C%20P%2C%20S.%20V.%2C%20Gowda%2C%20D.%20A.%2C%20H%2C%20K.%2C%20Damodar%2C%20S.%2C%20%26amp%3B%20Vyas%2C%20N.%20%282021%29.%20Exovesicular-Shh%20confers%20Imatinib%20resistance%20by%20upregulating%20Bcl2%20expression%20in%20chronic%20myeloid%20leukemia%20with%20variant%20chromosomes.%20%3Ci%3ECell%20Death%20%26amp%3B%20Disease%3C%5C%2Fi%3E%2C%20%3Ci%3E12%3C%5C%2Fi%3E%283%29%2C%201%26%23x2013%3B17.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41419-021-03542-w%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41419-021-03542-w%3C%5C%2Fa%3E%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.stemcellsciencenews.com%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D6445212%26amp%3Bitem_key%3DG58D8JUM%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Exovesicular-Shh%20confers%20Imatinib%20resistance%20by%20upregulating%20Bcl2%20expression%20in%20chronic%20myeloid%20leukemia%20with%20variant%20chromosomes%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Anusha%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hamza%22%2C%22lastName%22%3A%22Dalal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sitalakshmi%22%2C%22lastName%22%3A%22Subramanian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Snijesh%20V.%22%2C%22lastName%22%3A%22P%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Divya%20A.%22%2C%22lastName%22%3A%22Gowda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Krishnamurthy%22%2C%22lastName%22%3A%22H%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sharat%22%2C%22lastName%22%3A%22Damodar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Neha%22%2C%22lastName%22%3A%22Vyas%22%7D%5D%2C%22abstractNote%22%3A%22Chronic%20myeloid%20leukemia%20%28CML%29%20patients%20with%20complex%20chromosomal%20translocations%20as%20well%20as%20non-compliant%20CML%20patients%20often%20demonstrate%20short-lived%20responses%20and%20poor%20outcomes%20on%20the%20current%20therapeutic%20regimes%20using%20Imatinib%20and%20its%20variants.%20It%20has%20been%20derived%20so%20far%20that%20leukemic%20stem%20cells%20%28LSCs%29%20are%20responsible%20for%20Imatinib%20resistance%20and%20CML%20progression.%20Sonic%20hedgehog%20%28Shh%29%20signaling%20has%20been%20implicated%20in%20proliferation%20of%20this%20Imatinib-resistant%20CD34%28%2B%29%20LSCs.%20Our%20work%20here%20identifies%20the%20molecular%20mechanism%20of%20Shh-mediated%20mutation-independent%20Imatinib%20resistance%20that%20is%20most%20relevant%20for%20treating%20CML-variants%20and%20non-compliant%20patients.%20Our%20results%20elucidate%20that%20while%20Shh%20can%20impart%20stemness%2C%20it%20also%20upregulates%20expression%20of%20anti-apoptotic%20protein%5Cu2014Bcl2.%20It%20is%20the%20upregulation%20of%20Bcl2%20that%20is%20involved%20in%20conferring%20Imatinib%20resistance%20to%20the%20CD34%28%2B%29%20LSCs.%20Sub-toxic%20doses%20of%20Bcl2%20inhibitor%20or%20Shh%20inhibitor%20%28%3C%3CIC50%29%2C%20when%20used%20as%20adjuvants%20along%20with%20Imatinib%2C%20can%20re-sensitize%20Shh%20signaling%20cells%20to%20Imatinib.%20Our%20work%20here%20highlights%20the%20need%20to%20molecularly%20stratify%20CML%20patients%20and%20implement%20combinatorial%20therapy%20to%20overcome%20the%20current%20limitations%20and%20improve%20outcomes%20in%20CML.%22%2C%22date%22%3A%222021-03-11%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41419-021-03542-w%22%2C%22ISSN%22%3A%222041-4889%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.nature.com%5C%2Farticles%5C%2Fs41419-021-03542-w%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-03-12T18%3A12%3A05Z%22%7D%7D%5D%7D
Anusha, Dalal, H., Subramanian, S., P, S. V., Gowda, D. A., H, K., Damodar, S., & Vyas, N. (2021). Exovesicular-Shh confers Imatinib resistance by upregulating Bcl2 expression in chronic myeloid leukemia with variant chromosomes. Cell Death & Disease, 12(3), 1–17. https://doi.org/10.1038/s41419-021-03542-w Cite
